{"title": "Rheumatoid arthritis meets precision medicine", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/gene_therapy.xml", "value": "Rheumatoid arthritis meets precision medicine"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2018/03/180319124232.htm"}], "link": "https://www.sciencedaily.com/releases/2018/03/180319124232.htm", "summary": "Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study. In the near future, patients won't have to waste time and be disappointed with months of ineffective therapy, scientists said. Currently $2.5 billion a year is wasted on therapy that doesn't work.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/gene_therapy.xml", "value": "Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study. In the near future, patients won't have to waste time and be disappointed with months of ineffective therapy, scientists said. Currently $2.5 billion a year is wasted on therapy that doesn't work."}, "published": "Mon, 19 Mar 2018 12:42:32 EDT", "published_parsed": [2018, 3, 19, 16, 42, 32, 0, 78, 0], "id": "https://www.sciencedaily.com/releases/2018/03/180319124232.htm", "guidislink": false}